These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 947088

  • 1. Pharmacokinetics of Cytembena in chronic renal impairment.
    Schück O, Grafnetterová J, Sotorník I.
    Neoplasma; 1976; 23(2):161-70. PubMed ID: 947088
    [Abstract] [Full Text] [Related]

  • 2. The consequences of osmotic diuresis in residual nephrons for urinary drug excretion.
    Schück O, Nádvorniková H, Grafnetterová J, Pràt V.
    Int J Clin Pharmacol Biopharm; 1977 May; 15(5):201-4. PubMed ID: 873662
    [Abstract] [Full Text] [Related]

  • 3. Urinary excretion of drugs in chronic renal impairment with respect to changes their tubular handling by residual nephrons.
    Schück O, Grafnetterová J, Nádvorniková H, Prát V.
    Int J Clin Pharmacol Biopharm; 1976 Sep; 14(2):149-54. PubMed ID: 1036732
    [Abstract] [Full Text] [Related]

  • 4. Effect of rofecoxib on the glomerular filtration rate, proteinuria and the renin-angiotensin-aldosterone system in elderly subjects with chronic renal impairment.
    Horackova M, Schück O, Komers R, Charvat J, Teplan V, Kvapil M.
    Int J Clin Pharmacol Ther; 2005 Sep; 43(9):413-9. PubMed ID: 16163893
    [Abstract] [Full Text] [Related]

  • 5. Distribution of cytembena in rheumatic patients.
    Grafnetterová J, Smahel O, Truhlár P.
    Int J Clin Pharmacol; 1973 Nov; 8(3):185-8. PubMed ID: 4543927
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment.
    Türck D, Weber W, Sigmund R, Budde K, Neumayer HH, Fritsche L, Rominger KL, Feifel U, Slowinski T.
    J Clin Pharmacol; 2004 Feb; 44(2):163-72. PubMed ID: 14747425
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
    Strid S, Borgå O, Edenius C, Jostell KG, Odergren T, Weil A.
    Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
    [Abstract] [Full Text] [Related]

  • 8. Effect of chronic dietary protein intake on the renal function in healthy subjects.
    Brändle E, Sieberth HG, Hautmann RE.
    Eur J Clin Nutr; 1996 Nov; 50(11):734-40. PubMed ID: 8933120
    [Abstract] [Full Text] [Related]

  • 9. Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function.
    Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L.
    Nephrol Dial Transplant; 2006 Jul; 21(7):1855-62. PubMed ID: 16524933
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of oral cefatrizine in patients with impaired renal function.
    Couet W, Fauvel JP, Laville M, Pozet N, Fourtillan JB.
    Int J Clin Pharmacol Ther Toxicol; 1991 Jun; 29(6):213-7. PubMed ID: 1869342
    [Abstract] [Full Text] [Related]

  • 11. Dosage regimen of ranitidine in patients with renal impairment.
    Ebihara A, Ohashi K, Ikeda T, Yuhara M, Tagawa H, Yamakado M, Asano Y, Tabei K, Nakazawa K, Kondo K.
    Int J Clin Pharmacol Res; 1989 Jun; 9(1):1-7. PubMed ID: 2707920
    [Abstract] [Full Text] [Related]

  • 12. The plasma concentration and renal elimination of phenols in patients with chronic renal insufficiency.
    Schück O, Vidláková M, Erben J, Nádvorniková H, Teplan V, Reitschlägerová V.
    Czech Med; 1989 Jun; 12(2):117-24. PubMed ID: 2504560
    [Abstract] [Full Text] [Related]

  • 13. [Relation between creatinine clearance and glomerular filtration in various stages of chronic renal disease].
    Schück O, Teplan V, Nádvorńíková H, Skibová J.
    Vnitr Lek; 1992 Dec; 38(12):1181-6. PubMed ID: 1296347
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
    Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, Laskin OL.
    J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
    [Abstract] [Full Text] [Related]

  • 15. [Renal clearance of hippurate in persons with chronic renal insufficiency].
    Schück O, Spustová V, Dzúrik R, Teplan V, Nádvorníková H, Skibová J.
    Vnitr Lek; 1994 Jul; 40(7):407-10. PubMed ID: 8073654
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Concentration of cefadroxil in kidney tissue and serum after oral administration in patients with normal and impaired renal function].
    Degen J, Ringwelski L, Maier-Lenz H.
    Arzneimittelforschung; 1983 Jul; 33(9):1339-42. PubMed ID: 6685518
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The quinidine-digoxin interaction in patients with impaired renal function.
    Fichtl B, Doering W, Seidel H.
    Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):229-33. PubMed ID: 6862727
    [Abstract] [Full Text] [Related]

  • 20. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure.
    Haffner D, Schaefer F, Girard J, Ritz E, Mehls O.
    J Clin Invest; 1994 Mar; 93(3):1163-71. PubMed ID: 8132756
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.